Skip to main content
Clinical Trials/NCT04580628
NCT04580628
Completed
Not Applicable

Thuflep/SOLEP : Initial Experience and Results of Prostate Laser Enucleation With Thulium-fiber Laser (TFL)

Clinique Saint-Hilaire1 site in 1 country50 target enrollmentJuly 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Hyperplasia
Sponsor
Clinique Saint-Hilaire
Enrollment
50
Locations
1
Primary Endpoint
Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Thuflep TLF: initial experience and results of prostate laser enucleation with fibrous thulium laser (TLF)

Detailed Description

While prostate laser enucleation is being confirmed as the new gold standard for surgical management of benign prostate hypertrophy, the holmium:Yag laser is currently the most widely used. A new laser technology, the fibrous thulium laser (TFL), has recently appeared with clearly superior results for lithotripsy. The question therefore arises of the surgical and functional results of the use of fibrous thulium for prostate enucleation.

Registry
clinicaltrials.gov
Start Date
July 1, 2020
End Date
December 31, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
Clinique Saint-Hilaire
Responsible Party
Principal Investigator
Principal Investigator

MALVAL Benoit

Principal Investigator, Doctor in urology department

Clinique Saint-Hilaire

Eligibility Criteria

Inclusion Criteria

  • Patients superior or equal to 18 years old
  • Benign Prostate Hypertrophy ( more than 30cc.)
  • Indication to surgical treatment
  • No contraindication for surgery
  • No opposition to participating in the study

Exclusion Criteria

  • Evidence of urethral stenosis
  • Evidence of a bladder tumour
  • Evidence of prostate cancer known or confirmed by prostate biopsies if suspected
  • Known neurological bladder
  • Refusal to participate

Outcomes

Primary Outcomes

Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL

Time Frame: MONTH 12

self reported International Prostate Symptom Score (IPSS) From 0 (no symptom) to 35 (maximum symptoms)

Secondary Outcomes

  • duration of intervention(POST SURGERY HOUR 24)
  • max flow assessment(MONTH 1)
  • quality of life assessment(MONTH 1)
  • bloodloss assessment(Day 1)
  • Rate of post-operative complications(MONTH 6)
  • erectile dysfunction assessment(MONTH 1)
  • prostatic specific antigen in ng/mL level evolution(MONTH 1)
  • Measuring the evolution of Urinary Symptoms Rated by the IPSS Score after prostate laser enucleation with TFL(MONTH 6)
  • PATIENT GLOBAL IMPRESSION OF SEVERITY(MONTH 1)
  • post-void residual (PVR) urine test(MONTH 1)
  • PATIENT GLOBAL IMPRESSION OF IMPROVEMENT(MONTH 1)
  • urinary incontinence Assessment(MONTH 1)

Study Sites (1)

Loading locations...

Similar Trials